Table 3.

Sensitivity and specificity of individual studies for which meta-analysis was not performed because of insufficient number of studies

TPS Cut-off	Gold Standard Assay	Candidate Assay	Author	Year	Tumour Type	Sample Size	Sensitivity	Specificity
1%	PD-L1 IHC 22C3 pharmDx	SP142 LDT	Sakane et al.	2018	TC	53	1.00 (0.90–1.00)	0.53 (0.32–0.73)
			Soo et al.	2018	NSCLC	18	1.00 (0.77–1.00)	0.00 (0.00–0.43)
			Watanabe et al.	2018	M	32	0.83 (0.61–0.94)	0.86 (0.60–0.96)
		SP263 LDT	Sakane et al.	2018	TC	53	0.97 (0.85–1.0)	0.63 (0.41–0.81)
			Watanabe et al.	2018	M	32	0.78 (0.55-0.91)	0.93 (0.69–0.99)
		73-10 Assay	Tsao et al.	2018	NSCLC	81	1.00 (0.92–1.00)	0.53 (0.37–0.68)
	PD-L1 IHC 28-8 pharmDx	SP142 LDT	Sakane et al.	2018	TC	53	0.95 (0.84–0.99)	0.67 (0.39–0.86)
			Watanabe et al.	2018	M	32	0.82 (0.59–0.94)	0.80 (0.55–0.93)
		SP263 LDT	Sakane et al.	2018	TC	53	0.90 (0.78–0.96)	0.75 (0.47–0.91)
			Watanabe et al.	2018	M	32	0.88 (0.66–0.97)	1.00 (0.80–1.00)
		73-10 Assay	Tsao et al.	2018	NSCLC	81	0.96 (0.88–0.99)	0.63 (0.44–0.79)
	Ventana PD-L1 (SP263)	SP142 LDT	Soo et al.	2018	NSCLC	18	1.00 (0.80–1.00)	0.00 (0.00–0.56)
		73-10 Assay	Tsao et al.	2018	NSCLC	81	0.96 (0.87-0.99)	0.55 (0.38-0.71)
		22C3 LDT	Munari et al.	2018	NSCLC	184	0.66 (0.55–0.76)	0.99 (0.95–1.00)
50%	PD-L1 IHC 22C3 pharmDx	SP142 LDT	Sakane et al.	2018	TC	53	1.00 (0.85–1.00)	0.74 (0.56–0.86)
			Soo et al.	2018	NSCLC	18	1.00 (0.34–1.00)	0.75 (0.51–0.90)
			Watanabe et al.	2018	M	32	0.67 (0.21–0.94)	0.66 (0.47–0.45)
		SP263 LDT	Sakane et al.	2018	TC	53	0.82 (0.62–0.93)	0.97 (0.84–0.99)
			Watanabe et al.	2018	M	32	0.67 (0.21–0.94)	0.86 (0.69–0.70)
		73-10 Assay	Tsao et al.	2018	NSCLC	81	1.00 (0.80-1.00)	0.82 (0.71–0.89)
	Ventana PD-L1 (SP263)	SP142 LDT	Soo et al.	2018	NSCLC	18	1.00 (0.44–1.00)	0.80 (0.55–0.93)
		22C3 LDT	Munari et al.	2018	NSCLC	184	0.64 (0.45–0.80)	0.99 (0.97–1.00)
		73-10 Assay	Tsao et al.	2018	NSCLC	81	0.94 (0.74–0.99)	0.84 (0.73–0.91)

L NSCLC, M mesothelioma, U UC, TC Thymic Carcinoma